A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled 26-Week Dose-Response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes.

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled 26-Week Dose-Response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Rivoglitazone (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Apr 2010 Results published in Current Medical Research and Opinion.
    • 10 Sep 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top